Monday, March 21, 2016
Amgen Reports Positive Results In Ostereoposis Study
Thousand Oaks-based Amgen reports that it saw positive top-line results for a study for its romosozumab compound in men with osteoporosis. Amgen said its Phase 3 study demonstrated a significant increase in bone mineral density (BMD) at the lumbar spine, compared with a placebo over 12 months. The study and compound are being develops in a collaboration between Amgen and UCB. Romosozumab is being targeted at both treating women and men with osteoporosis.